The American Journal of Psychiatry
Journal Home Search Current Issue Past Issues Subscribe All APPI Journals Help Contact Us
 
Quicksearch
Advanced Search
Or Search All APPI Journals
This Article
* Full Text
* Full Text (PDF)
* Alert me when this article is cited
* Alert me if a correction is posted
* Citation Map
Services
* Email this article to a Colleague
* Similar articles in this journal
* Similar articles in PubMed
* Alert me to new issues of the journal
* Add to My Articles & Searches
* Download to citation manager
* reprints & permissions
Citing Articles
* Citing Articles via HighWire
* Citing Articles via Google Scholar
Google Scholar
* Articles by Woerner, M. G.
* Articles by Kane, J. M.
* Search for Related Content
PubMed
* PubMed Citation
* Articles by Woerner, M. G.
* Articles by Kane, J. M.
Related Collections
* Atypical Neuroleptics
* Schizophrenia Spectrum Disorders
Am J Psychiatry 160:1514-1516, August 2003
© 2003 American Psychiatric Association


Brief Report

Clozapine as a First Treatment for Schizophrenia

Margaret G. Woerner, Ph.D., Delbert G. Robinson, M.D., Jose Ma. J. Alvir, Dr.P.H., Brian B. Sheitman, M.D., Jeffrey A. Lieberman, M.D., and John M. Kane, M.D.

OBJECTIVE: The authors’ goal was to explore whether clozapine given as the first antipsychotic treatment favorably affects the course of schizophrenia. METHOD: Thirty-four inpatients experiencing their first episode of schizophrenia or schizoaffective disorder were treated first with clozapine and then followed for up to 4 years. In a previous study, the authors followed patients experiencing their first episode of schizophrenia or schizoaffective disorder who were given fluphenazine as the first treatment. In the current study and the previous study, response criteria required sustained remission of positive symptoms. RESULTS: Nineteen of the 34 subjects met response criteria while taking clozapine. The median time to treatment response was 11 weeks (range=2–13). Using survival analysis, the authors determined that the cumulative response rate for the 34 patients was 66.4% at the end of 13 weeks, which is comparable to the response rate to fluphenazine in the previous study. All responses to clozapine occurred by 13 weeks. Eight (42%) of the clozapine responders discontinued clozapine before 6 months, and only six (32%) remained on clozapine for all of their time in the study. CONCLUSIONS: The authors found no benefit for clozapine over conventional antipsychotics for acute treatment of the first episode of schizophrenia or schizoaffective disorder. Long-term benefits could not be studied because of the high rate of early discontinuation of clozapine treatment.




This article has been cited by other articles:


Home page
FocusHome page
J. M. Kane
New-Onset Schizophrenia: Pharmacologic Treatment
Focus, April 1, 2008; 6(2): 167 - 171.
[Abstract] [Full Text] [PDF]


Home page
Schizophr BullHome page
D. G Robinson, M. G Woerner, H. M Delman, and J. M Kane
Pharmacological Treatments for First-Episode Schizophrenia
Schizophr Bull, July 1, 2005; 31(3): 705 - 722.
[Abstract] [Full Text] [PDF]


Home page
Am. J. PsychiatryHome page
D. E. ROSS
Clozapine and Typical Antipsychotics
Am J Psychiatry, October 1, 2004; 161(10): 1925 - 1926.
[Full Text] [PDF]




Get information about faster international access.

Privacy Policy

Copyright © 2003 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us

American Psychiatric Publishing, Inc. American Psychiatric Association
1000 Wilson Boulevard, Suite 1825, Arlington, VA 22209-3901 * 800-368-5777 * appi at psych.org